Intellectual Property Estate

MedMira believes that our rapid flow-through technology (RFT) platform and the methodology behind our rapid diagnostics are among the Company’s most valuable assets.  As such, we have taken steps to protect these assets with patents in key international markets.  Several key patents have been awarded to MedMira and others are pending.

MedMira’s intellectual property (IP) estate includes the following:

United States
Patent No. 10/163,675

European Union
European Patent Application No.  EP1417489

China
Chinese Patent  No. 02819646.5